Numbered references not directly listed in protocols (list also contains general references used to validate assays):

  1. Roth, B., M. Laskowski, and C. Coscia. - Evidence for distinct subcellular sites of opiate receptors. Demonstration of opiate receptors in smooth microsomal fractions isolated from rat rain. J Biol Chem 256(19):10017-23 (1981).

  2. Roth, B. L., M. B. Laskowski, and C. J. Coscia. Microsomal opiate receptors differ from synaptic membrane receptors in proteolytic sensitivity. Brain Res 250(1):101-9 (1982).

  3. Roth, B. L., M. W. Laskowski, and C. J. Coscia. Microsomal opiate receptors differ from synaptic membrane receptors in proteolytic sensitivity. Brain Research 250:101-109 (1982).

  4. Roth, B. L., T. Nakaki, D. M. Chuang, and E. Costa. Aortic recognition sites for serotonin (5HT) are coupled to phospholipase C and modulate phosphatidylinositol turnover. Neuropharmacology 23(10):1223-5 (1984).

  5. Roth, B. L., and C. J. Coscia. Microsomal opiate receptors: characterization of smooth microsomal and synaptic membrane opiate receptors. J Neurochem 42(6):1677-84 (1984).

  6. Roth, B. L., M. C. Beinfeld, and A. C. Howlett. Secretin receptors on neuroblastoma cell membranes: characterization of 125I-labeled secretin binding and association with adenylate cyclase. J Neurochem 42(4):1145-52 (1984).

  7. Roth, B. L., D. B. Bennett, K. Pryhuber, S. Scheibe, and C. J. Coscia. Slowly dissociating form of bovine hippocampusopiate receptor, in Investigation of membrane located receptors (E. Reid, G. M. W. Cook and D. J. Morre, eds.). Plenum, New York, 489-492 (1984).

  8. Roth, B. L., and M. C. Beinfeld. The postnatal development of VIP binding sites in rat forebrain and hindbrain. Peptides 6(1):27-30 (1985).

  9. Roth, B. L., T. Nakaki, D. M. Chuang, and E. Costa. 5-Hydroxytryptamine2 receptors coupled to phospholipase C in rat aorta: modulation of phosphoinositide turnover by phorbol ester. J Pharmacol Exp Ther 238(2):480-5 (1986).

  10. Roth, B. L., S. McLean, X. Z. Zhu, and D. M. Chuang. Characterization of two [3H]ketanserin recognition sites in rat striatum. J Neurochem 49(6):1833-8 (1987).

  11. Roth, B. L., and J. A. Spitzer. Altered hepatic vasopressin and alpha 1-adrenergic receptors after chronic endotoxin infusion. Am J Physiol 252(5 Pt 1):E699-702 (1987).

  12. Roth, B. L., S. McLean, X.-Z. Zhu, and D.-M. Chuang. Characterization of two [3H]-ketanserin recognition sites in rat striatum. Journal of Neurochemistry 49:1833-1838 (1987).

  13. Roth, B. L., and J. A. Spitzer. Alterations in alpha1-adrenergic and vasopressin receptors after chronic endotoxin infusion. American Journal of Physiology 252:E699-E702 (1987).

  14. Roth, B., M. Hamblin, and R. Ciaranello. Regulation of 5-HT2 and 5-HT1C serotonin receptor levels. Methodology and mechanisms. Neuropsychopharmacology 3(5-6):427-33 (1990).

  15. Roth, B. L., and R. D. Ciaranello. Chronic mianserin treatment decreases 5-HT2 receptor binding without altering 5-HT2 receptor mRNA levels. Eur J Pharmacol 207(2):169-72 (1991).

  16. Roth, B. L., M. W. Hamblin, and R. D. Ciaranello. Developmental regulation of 5-HT2 and 5-HT1c mRNA and receptor levels. Brain Res Dev Brain Res 58(1):51-8 (1991).

  17. Roth, B. L., S. C. Craigo, M. S. Choudhary, A. Uluer, F. J. Monsma, Jr., Y. Shen, H. Y. Meltzer, and D. R. Sibley. Binding of typical and atypical antipsychotic agents to 5- hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268(3):1403-10 (1994).

  18. Roth, B. L., R. D. Ciaranello, and H. Y. Meltzer. Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther 260(3):1361-5 (1992).

  19. Roth, B. L., E. P. Palvimaki, S. Berry, N. Khan, N. Sachs, A. Uluer, and M. S. Choudhary. 5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation. J Pharmacol Exp Ther 275(3):1638-46 (1995).

  20. Roth, B. L., S. Tandra, L. H. Burgess, D. R. Sibley, and H. Y. Meltzer. D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl) 120(3):365-8 (1995).

  21. Roth, B.,et al. - 5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation. J Pharmacol Exp Ther 275(3):1638-46 (1995).

  22. Roth, B. H., EG. Pharmacology of 5-HT2 receptors, 367-394 (1997).

  23. Roth, B., M. Shoham, M. Choudhary, and N. Khan. Identification of conserved aromatic residues essential for agonist binding and efficacy at 5-HT2A receptors. Molecular Pharmacology 52:259-266 (1997).

  24. Roth, B., H. Meltzer, and N. Khan. Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors, in Advances in Pharmacology. Academic Press, San Diego, 482-485 (1998).

  25. Roth, B., D. Willins, K. Kristiansen, and W. Kroeze. 5-HT2-family receptors (5-HT2A, 5-HT2B, 5-HT2C): where structure meets function. Pharmacol Therap (1998).

  26. Roth, B., S. Berry, and W. Kroeze. Molecular mechanisms of serotonin 5-HT2A receptor regulation. Crit Rev. Neurobio (1998).

  27. Roth, B., D. Willins, K. Kristiansen, and W. Kroeze. Activation is hallucinogenic and antagonism is therapeutic: role of 5-HT2A receptors in atypical antipsychotic drug actions. The Neuroscientist in press (1998).

  28. Roth, B., D. Willins, and W. Kroeze. G protein-coupled receptor (GPCR) trafficking in the central nervous system: relevance for drugs of abuse. Drug Alcohol Depend (1998).

  29. Bennett, D., J. Spain, M. Laskowski, B. Roth, and C. Coscia. - Stereospecific opiate-binding sites occur in coated vesicles. J Neurosci 5(11):3010-5 (1985).

  30. Berry, S., M. Shah, N. Khan, and B. Roth. Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro. Mol Pharmacol 50(2):306-13 (1996).

  31. Carcillo, J. A., R. Z. Litten, E. A. Suba, and B. L. Roth. Alterations in rat aortic alpha 1-adrenoceptors and alpha 1-adrenergic stimulated phosphoinositide hydrolysis in intraperitoneal sepsis. Circ Shock 26(3):331-9 (1988).

  32. Chaudhary, S., S. Craigo, and B. L. Roth. Identification of domains which modify serotonin receptor pharmacology. Society for Neurosciences Abstracts :in press (1992).

  33. Chuang, D. M., O. Dillon-Carter, J. W. Spain, M. B. Laskowski, B. L. Roth, and C. J. Coscia. Detection and characterization of beta-adrenergic receptors and adenylate cyclase in coated vesicles isolated from bovine brain. J Neurosci 6(9):2578-84 (1986).

  34. Kohen, R., M. A. Metcalf, N. Khan, T. Druck, K. Huebner, J. E. Lachowicz, H. Y. Meltzer, D. R. Sibley, B. L. Roth, and M. W. Hamblin. Cloning, characterization, and chromosomal localization of a human 5- HT6 serotonin receptor. J Neurochem 66(1):47-56 (1996).

  35. Legan, E., J. Parillo, B. Chernow, and B. L. Roth. Activation of phosphatidylinositol turnover in rat aorta by alpha1-adrenergic receptor activation. European Journal of Pharmacology 110:389-390 (1985).

  36. McLean, S., R. B. Rothman, D. M. Chuang, K. C. Rice, J. W. Spain, C. J. Coscia, and B. L. Roth. Cross-linking of [125I]beta-endorphin to mu-opioid receptors during development. Brain Res Dev Brain Res 45(2):283-9 (1989).

  37. McMillan, M., B. Chernow, and B. L. Roth. Hepatic alpha 1-adrenergic receptor alteration in a rat model of chronic sepsis. Circ Shock 19(2):185-93 (1986).

  38. Nakaki, T., B. L. Roth, D. M. Chuang, and E. Costa. 5-Hydroxytryptamine uptake and imipramine binding sites in neurotumor NCB-20 cells. J Neurochem 45(3):920-5 (1985).

  39. Nakaki, T., B. L. Roth, D. M. Chuang, and E. Costa. Phasic and tonic components in 5-HT2 receptor-mediated rat aorta contraction: participation of Ca++ channels and phospholipase C. J Pharmacol Exp Ther 234(2):442-6 (1985).

  40. Nash, J. F., B. L. Roth, J. D. Brodkin, D. E. Nichols, and G. A. Gudelsky. Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors. Neurosci Lett 177(1-2):111-5 (1994).

  41. Nichols, D. E., S. Frescas, D. Marona-Lewicka, X. Huang, B. L. Roth, G. A. Gudelsky, and J. F. Nash. 1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist. J Med Chem 37(25):4346-51 (1994).

  42. Nicoletti, F., J. L. Meek, M. J. Iadarola, D. M. Chuang, B. L. Roth, and E. Costa. Coupling of inositol phospholipid metabolism with excitatory amino acid recognition sites in rat hippocampus. J Neurochem 46(1):40-6 (1986).

  43. Palvimaki, E. P., B. L. Roth, H. Majasuo, A. Laakso, M. Kuoppamaki, E. Syvalahti, and J. Hietala. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl) 126(3):234-40 (1996).

  44. Spain, J. W., D. B. Bennett, B. L. Roth, and C. J. Coscia. Ontogeny of benzomorphan-selective (kappa) sites: a computerized analysis. Life Sci 33 Suppl 1:235-8 (1983).

  45. Spain, J. W., B. L. Roth, and C. J. Coscia. Differential ontogeny of multiple opioid receptors (mu, delta, and kappa). J Neurosci 5(3):584-8 (1985).

  46. Scheibe, S. D., D. B. Bennett, J. W. Spain, B. L. Roth, and C. J. Coscia. Kinetic evidence for differential agonist and antagonist binding to bovine hippocampal synaptic opiate receptors. Journal of Biological Chemistry 259:13298-13303 (1984).

  47. Suba, E. A., and B. L. Roth. Prostaglandins activate phosphoinositide metabolism in rat aorta. Eur J Pharmacol 136(3):325-32 (1987).

  48. Wohltmann, M., B. L. Roth, and C. J. Coscia. Differential postnatal development of mu and delta opiate receptors. Brain Res 255(4):679-84 (1982).

  49. Arango, V., P. Ernsberger, P. M. Marzuk, and e. al. Autoradiographic demonstration of increased serotonin 5-HT2 and beta-adrenergic receptor binding sites in the brains of suicide victims. Archives of General Psychiatry 47:1038-1047 (1990).

  50. Arango, V., P. Ernsberger, D. J. Reis, and J. J. Mann. Demonstration of high- and low-affinity beta-adrenergic receptors in slide-mounted sections of rat and human brain. Brain Res 516(1):113-121 (1990).

  51. Arango, V., P. Ernsberger, A. F. Sved, and J. J. Mann. Quantitative autoradiography of alpha 1- and alpha 2-adrenergic receptors in the cerebral cortex of controls and suicide victims. Brain Res 630(1-2):271-282 (1993).

  52. Buccafusco, J. J., C. A. Lapp, K. L. Westbrooks, and P. Ernsberger. Role of medullary I1-imidazoline and alpha 2-adrenergic receptors in the antihypertensive responses evoked by central administration of clonidine analogs in conscious spontaneously hypertensive rats. J Pharmacol Exp Ther 273(3):1162-1171 (1995).

  53. Coles, S. K., P. Ernsberger, and T. E. Dick. A role for NMDA receptors in posthypoxic frequency decline in the rat. Am J Physiol 274(6):R1546-R1555 (1998).

  54. Ernsberger, P., and D. C. U'Prichard. Para-azidoclonidine: a novel photoaffinity ligand for the alpha 2- receptor. Life Sci 38(17):1557-1563 (1986).

  55. Ernsberger, P., M. P. Meeley, J. J. Mann, and D. J. Reis. Clonidine binds to imidazole binding sites as well as alpha 2- adrenoceptors in the ventrolateral medulla. Eur J Pharmacol 134(1):1-13 (1987).

  56. Ernsberger, P., and D. C. U'Prichard. Modulation of agonist and antagonist interactions at kidney alpha 1- adrenoceptors by nucleotides and metal ions. Eur J Pharmacol 133(2):165-176 (1987).

  57. Ernsberger, P., S. P. Arneric, V. Arango, and D. J. Reis. Quantitative distribution of muscarinic receptors and choline acetyltransferase in rat medulla: examination of transmitter-receptor mismatch. Brain Res 452(1-2):336-344 (1988).

  58. Ernsberger, P., V. Arango, and D. J. Reis. A high density of muscarinic receptors in the rostral ventrolateral medulla of the rat is revealed by correction for autoradiographic efficiency. Neurosci Lett 85(2):179-186 (1988).

  59. Ernsberger, P., J. Zhou, T. H. Damon, and J. G. Douglas. Angiotensin II receptor subtypes in cultured rat renal mesangial cells. Am J Physiol 263(3):F411-F416 (1992).

  60. Haxhiu-Poskurica, B., P. Ernsberger, M. A. Haxhiu, M. J. Miller, L. Cattarossi, and R. J. Martin. Development of cholinergic innervation and muscarinic receptor subtypes in piglet trachea. Am J Physiol 264(6):L606-L614 (1993).

  61. Lei, L., M. Slavica, P. Ernsberger, M. E. Graves, P. Patil, D. Miller, and D. Feller. Calcium channel-dependent and I1-imidazoline receptor binding properties of 2-(4'-isothiocyanatobenzyl) imidazoline analogs in vascular and brain tissues. Ann N Y Acad Sci 763:283-286 (1995).

  62. Kou, Y. R., P. Ernsberger, P. A. Cragg, N. S. Cherniack, and N. R. Prabhakar. Role of alpha 2-adrenergic receptors in the carotid body response to isocapnic hypoxia. Respir Physiol 83(3):353-364 (1991).

  63. Liedtke, C. M., J. Furin, and P. Ernsberger. Alpha 2-adrenergic, but not imidazole, agonists activate NaCl cotransport in rabbit tracheal epithelial cells. Am J Physiol 264(3):C568-C576 (1993).

  64. Piletz, J. E., A. Halaris, and P. R. Ernsberger. Psychopharmacology of imidazoline and alpha 2-adrenergic receptors: implications for depression. Crit Rev Neurobiol 9(1):29-66 (1994).

  65. Separovic, D., M. Kester, and P. Ernsberger. Coupling of I1-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells. Mol Pharmacol 49(4):668-675 (1996).

  66. Zhou, J., P. Ernsberger, and J. G. Douglas. A novel angiotensin receptor subtype in rat mesangium. Coupling to adenylyl cyclase. Hypertension 21(6):1035-1038 (1993).

  67. Zheng, L., M. S. Berridge, and P. Ernsberger. Synthesis, binding properties, and 18F labeling of fluorocarazolol, a high-affinity beta-adrenergic receptor antagonist. J Med Chem 37(20):3219-3230 (1994).

  68. Yohannan, M. D., and P. Ernsberger. Heterogeneity of neurokinin1 binding sites in porcine respiratory tract. Peptides 16(5):873-882 (1995).

  69. Beattie, C. E., B. Kolva, and R. E. Siegel. GABAA receptor subunit mRNA expression in the weaver cerebellum: modulation by cell-cell interactions. Brain Res Dev Brain Res 88(2):171-177 (1995).

  70. Beattie, C. E., and R. E. Siegel. Developmental cues modulate GABAA receptor subunit mRNA expression in cultured cerebellar granule neurons. J Neurosci 13(4):1784-1792 (1993).

  71. Behringer, K. A., L. M. Gault, and R. E. Siegel. Differential regulation of GABA A receptor subunit mRNAs in rat cerebellar granule neurons: importance of environmental cues. J Neurochem 66(4):1347-1353 (1996).

  72. Gambarana, C., R. Pittman, and R. E. Siegel. Developmental expression of the GABAA receptor alpha 1 subunit mRNA in the rat brain. J Neurobiol 21(8):1169-1179 (1990).

  73. Gambarana, C., C. E. Beattie, Z. R. Rodriguez, and R. E. Siegel. Region-specific expression of messenger RNAs encoding GABAA receptor subunits in the developing rat brain. Neuroscience 45(2):423-432 (1991).

  74. Gault, L. M., and R. E. Siegel. NMDA receptor stimulation selectively initiates GABA(A) receptor delta subunit mRNA expression in cultured rat cerebellar granule neurons. J Neurochem 70(5):1907-1915 (1998).

  75. Gault, L. M., and R. E. Siegel. Expression of the GABAA Receptor delta Subunit Is Selectively Modulated by Depolarization in Cultured Rat Cerebellar Granule Neurons. J Neurosci 17(7):2391-2399 (1997).

  76. Nadler, L. S., E. R. Guirguis, and R. E. Siegel. GABAA receptor subunit polypeptides increase in parallel but exhibit distinct distributions in the developing rat cerebellum. J Neurobiol 25(12):1533-1544 (1994).

  77. Nadler, L. S., L. T. Raetzman, K. L. Dunkle, N. Mueller, and R. E. Siegel. GABAA receptor subunit expression and assembly in cultured rat cerebellar granule neurons. Brain Res Dev Brain Res 97(2):216-225 (1996).

  78. Siegel, R. E. The mRNAs encoding GABAA/benzodiazepine receptor subunits are localized in different cell populations of the bovine cerebellum. Neuron 1(7):579-584 (1988).

  79. Atack, J. R., G. L. Wenk, M. V. Wagster, K. J. Kellar, P. J. Whitehouse, and S. I. Rapoport. Bilateral changes in neocortical [3H]pirenzepine and [3H]oxotremorine-M binding following unilateral lesions of the rat nucleus basalis magnocellularis: an autoradiographic study. Brain Res 483(2):367-372 (1989).

  80. Bergstrom, D. A., and K. J. Kellar. Adrenergic and serotonergic receptor binding in rat brain after chronic desmethylimipramine treatment. Journal of Pharmacology and Experimental Therapeutics 209:256-261 (1979).

  81. Bergstrom, D. A., and K. J. Kellar. Effect of electroconvulsive shock on monoaminergic receptor binding sites in rat brain. Nature 278(5703):464-466 (1979).

  82. Blendy, J. A., C. A. Stockmeier, and K. J. Kellar. Electroconvulsive shock and reserpine increase alpha 1-adrenoceptor binding sites but not norepinephrine-stimulated phosphoinositide hydrolysis in rat brain. Eur J Pharmacol 156(2):267-270 (1988).

  83. Blendy, J. A., D. C. Perry, L. A. Pabreza, and K. J. Kellar. Electroconvulsive shock increases alpha 1b- but not alpha 1a- adrenoceptor binding sites in rat cerebral cortex. J Neurochem 57(5):1548-1555 (1991).

  84. Cascio, C. S., and K. J. Kellar. Characterization of [3H]tryptamine binding sites in brain. Eur J Pharmacol 95(1-2):31-39 (1983).

  85. Davila-Garcia, M. I., J. L. Musachio, D. C. Perry, Y. Xiao, A. Horti, E. D. London, R. F. Dannals, and K. J. Kellar. [125I]IPH, an epibatidine analog, binds with high affinity to neuronal nicotinic cholinergic receptors. J Pharmacol Exp Ther 282(1):445-451 (1997).

  86. Gillis, R. A., K. J. Hill, J. S. Kirby, J. A. Quest, P. Hamosh, W. P. Norman, and K. J. Kellar. Effect of activation of central nervous system serotonin 1A receptors on cardiorespiratory function. J Pharmacol Exp Ther 248(2):851-857 (1989).

  87. Grimm, L. J., J. A. Blendy, K. J. Kellar, and D. C. Perry. Chronic reserpine administration selectively up-regulates beta 1- and alpha 1b-adrenergic receptors in rat brain: an autoradiographic study. Neuroscience 47(1):77-86 (1992).

  88. Houghtling, R. A., M. I. Davila-Garcia, and K. J. Kellar. Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain. Mol Pharmacol 48(2):280-287 (1995).

  89. Kellar, K. J., C. S. Cascio, D. A. Bergstrom, J. A. Butler, and P. Iadarola. Electroconvulsive shock and reserpine: effects on beta-adrenergic receptors in rat brain. J Neurochem 37(4):830-836 (1981).

  90. Kellar, K. J., and D. A. Bergstrom. Electroconvulsive shock: effects and biochemical correlates of neurotransmitter receptors in rat brain. Neuropharmacology 22:401-406 (1983).

  91. Kellar, K. J., C. A. Stockmeier, and A. M. Martino. Regulation of beta adrenergic and serotonin-S2 receptors in brain by electroconvulsive shock and serotonin. Psychopharmacol Ser 3:99-106 (1987).

  92. Perry, D. C., and K. J. Kellar. [3H]epibatidine labels nicotinic receptors in rat brain: an autoradiographic study. J Pharmacol Exp Ther 275(2):1030-1034 (1995).

  93. Stockmeier, C. A., A. M. Martino, and K. J. Kellar. A strong influence of serotonin axons on beta-adrenergic receptors in rat brain. Science 230(4723):323-325 (1985).

  94. Stockmeier, C. A., and K. J. Kellar. Serotonin depletion unmasks serotonergic component of [3H]dihydroalprenolol binding in rat brain. Mol Pharmacol 36(6):903-911 (1989).

  95. Whitehouse, P. J., A. M. Martino, M. V. Wagster, D. L. Price, R. Mayeux, J. R. Atack, and K. J. Kellar. Reductions in [3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study. Neurology 38(5):720-723 (1988).

  96. Whitehouse, P. J., A. M. Martino, K. A. Marcus, R. M. Zweig, H. S. Singer, D. L. Price, and K. J. Kellar. Reductions in acetylcholine and nicotine binding in several degenerative diseases. Arch Neurol 45(7):722-724 (1988).

  97. Whitehouse, P. J., and K. J. Kellar. Nicotinic and muscarinic cholinergic receptors in Alzheimer's disease and related disorders. J Neural Transm Suppl 24:175-182 (1987).

  98. Danysz, W., J. T. Wroblewski, and E. Costa. Learning impairment in rats by N-methyl-D-aspartate receptor antagonists. Neuropharmacology 27(6):653-656 (1988).

  99. Danysz, W., E. Fadda, J. T. Wroblewski, and E. Costa. Different modes of action of 3-amino-1-hydroxy-2-pyrrolidone (HA-966) and 7-chlorokynurenic acid in the modulation of N-methyl-D-aspartate- sensitive glutamate receptors. Mol Pharmacol 36(6):912-916 (1989).

  100. Danysz, W., J. T. Wroblewski, G. Brooker, and E. Costa. Modulation of glutamate receptors by phencyclidine and glycine in the rat cerebellum: cGMP increase in vivo. Brain Res 479(2):270-276 (1989).

  101. Danysz, W., E. Fadda, J. T. Wroblewski, and E. Costa. Kynurenate and 2-amino-5-phosphonovalerate interact with multiple binding sites of the N-methyl-D-aspartate-sensitive glutamate receptor domain. Neurosci Lett 96(3):340-344 (1989).

  102. Danysz, W., E. Fadda, J. T. Wroblewski, and E. Costa. [3H]D-serine labels strychnine-insensitive glycine recognition sites of rat central nervous system. Life Sci 46(3):155-164 (1990).

  103. Danysz, W., and J. T. Wroblewski. Concanavalin A increases N-methyl-D-aspartate-induced Ca2+ influx in cerebellar granule cells in culture. Pol J Pharmacol 47(1):31-36 (1995).

  104. Kiedrowski, L., E. Costa, and J. T. Wroblewski. Glutamate receptor agonists stimulate nitric oxide synthase in primary cultures of cerebellar granule cells. J Neurochem 58(1):335-341 (1992).

  105. Kozikowski, A. P., W. Tuckmantel, I. J. Reynolds, and J. T. Wroblewski. Synthesis and bioactivity of a new class of rigid glutamate analogues. Modulators of the N-methyl-D-aspartate receptor. J Med Chem 33(6):1561-1571 (1990).

  106. Kozikowski, A. P., W. Tuckmantel, Y. Liao, H. Manev, S. Ikonomovic, and J. T. Wroblewski. Synthesis and metabotropic receptor activity of the novel rigidified glutamate analogues (+)- and (-)-trans-azetidine-2,4-dicarboxylic acid and their N-methyl derivatives. J Med Chem 36(18):2706-2708 (1993).

  107. Kozikowski, A. P., D. Steensma, G. L. Araldi, W. Tuckmantel, S. Wang, S. Pshenichkin, E. Surina, and J. T. Wroblewski. Synthesis and biology of the conformationally restricted ACPD analogue, 2-aminobicyclo[2.1.1]hexane-2,5-dicarboxylic acid-I, a potent mGluR agonist. J Med Chem 41(10):1641-1650 (1998).

  108. Lazarewicz, J. W., J. T. Wroblewski, M. E. Palmer, and E. Costa. Activation of N-methyl-D-aspartate-sensitive glutamate receptors stimulates arachidonic acid release in primary cultures of cerebellar granule cells. Neuropharmacology 27(7):765-769 (1988).

  109. Lazarewicz, J. W., J. T. Wroblewski, and E. Costa. N-methyl-D-aspartate-sensitive glutamate receptors induce calcium- mediated arachidonic acid release in primary cultures of cerebellar granule cells. J Neurochem 55(6):1875-1881 (1990).

  110. Nicoletti, F., J. T. Wroblewski, A. Novelli, A. Guidotti, and E. Costa. Excitatory amino acid signal transduction in cerebellar cell cultures. Funct Neurol 1(4):345-349 (1986).

  111. Nicoletti, F., J. T. Wroblewski, A. Novelli, H. Alho, A. Guidotti, and E. Costa. The activation of inositol phospholipid metabolism as a signal- transducing system for excitatory amino acids in primary cultures of cerebellar granule cells. J Neurosci 6(7):1905-1911 (1986).

  112. Nicoletti, F., M. J. Iadarola, J. T. Wroblewski, and E. Costa. Excitatory amino acid recognition sites coupled with inositol phospholipid metabolism: developmental changes and interaction with alpha 1-adrenoceptors. Proc Natl Acad Sci U S A 83(6):1931-1935 (1986).

  113. Wroblewska, B., J. T. Wroblewski, O. H. Saab, and J. H. Neale. N-acetylaspartylglutamate inhibits forskolin-stimulated cyclic AMP levels via a metabotropic glutamate receptor in cultured cerebellar granule cells. J Neurochem 61(3):943-948 (1993).

  114. Wroblewska, B., J. T. Wroblewski, S. Pshenichkin, A. Surin, S. E. Sullivan, and J. H. Neale. N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J Neurochem 69(1):174-181 (1997).

  115. Wroblewski, J. T., F. Nicoletti, and E. Costa. Different coupling of excitatory amino acid receptors with Ca2+ channels in primary cultures of cerebellar granule cells. Neuropharmacology 24(9):919-921 (1985).

  116. Wroblewski, J. T., and W. Danysz. Modulation of glutamate receptors: molecular mechanisms and functional implications. Annu Rev Pharmacol Toxicol 29:441-474 (1989).

  117. Wroblewski, J. T., F. Nicoletti, E. Fadda, and E. Costa. Phencyclidine is a negative allosteric modulator of signal transduction at two subclasses of excitatory amino acid receptors. Proc Natl Acad Sci U S A 84(14):5068-5072 (1987).

  118. Spain, J. W., B. L. Roth, and C. J. Coscia. Differential ontogeny of multiple opioid receptors (mu, delta, kappa). Journal of Neuroscience 5:584-588 (1985).

  119. Roth, B. L., M. C. Beinfeld, and A. W. Howlett. Secretin receptors on neuroblastoma cells. Journal of Neurochemistry 42:1145-1152 (1984).

  120. Dulin, N. O., P. Ernsberger, D. J. Suciu, and J. G. Douglas. Rabbit renal epithelial angiotensin II receptors. Am J Physiol 267(5):F776-F782 (1994).

  121. Ernsberger, P., R. J. Koletsky, L. A. Collins, and J. G. Douglas. Renal angiotensin receptor mapping in obese spontaneously hypertensive rats. Hypertension 21(6):1039-1045 (1993).

  122. Madhun, Z. T., P. Ernsberger, F. C. Ke, J. Zhou, U. Hopfer, and J. G. Douglas. Signal transduction mediated by angiotensin II receptor subtypes expressed in rat renal mesangial cells. Regul Pept 44(2):149-157 (1993).

  123. Griffith, J. M., J. E. O'Neill, F. Petty, D. Garver, D. Young, and R. Freedman. Nicotinic receptor desensitization and sensory gating deficits in schizophrenia. Biol Psychiatry 44(2):98-106 (1998).

  124. Lena, C., and J. P. Changeux. Pathological mutations of nicotinic receptors and nicotine-based therapies for brain disorders. Curr Opin Neurobiol 7(5):674-682 (1997).

  125. Freedman, R., H. Coon, M. Myles-Worsley, A. Orr-Urtreger, A. Olincy, A. Davis, M. Polymeropoulos, J. Holik, J. Hopkins, M. Hoff, J. Rosenthal, M. C. Waldo, F. Reimherr, P. Wender, J. Yaw, D. A. Young, C. R. Breese, C. Adams, D. Patterson, L. E. Adler, L. Kruglyak, S. Leonard, and W. Byerley. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A 94(2):587-592 (1997).

  126. Sanberg, P. R., A. A. Silver, R. D. Shytle, M. K. Philipp, D. W. Cahill, H. M. Fogelson, and B. J. McConville. Nicotine for the treatment of Tourette's syndrome. Pharmacol Ther 74(1):21-25 (1997).

  127. Dursun, S. M., and M. A. Reveley. Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette's syndrome: an open study. Psychol Med 27(2):483-487 (1997).

  128. Silver, A. A., R. D. Shytle, M. K. Philipp, and P. R. Sanberg. Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 35(12):1631-1636 (1996).

  129. Roth, B. L., M. S. Choudhary, N. Khan, and A. Z. Uluer. High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model. J Pharmacol Exp Ther 280(2):576-83 (1997).

  130. Fargin, A., J. R. Raymond, J. W. Regan, S. Cotecchia, R. J. Lefkowitz, and M. G. Caron. The genomic clone G-21 which resembles a beta-adrenergic receptor sequence encodes the 5-HT1A receptor. Nature 335:358-360 (1988).

  131. Hamblin, M. W., and M. A. Metcalf. Cloning of a human 5-HT1d serotonin receptor gene and its rat homologue. Society for Neurosciences Abstracts 17:719 (1991).

  132. McAllister, G., A. Charlesworth, C. Snodin, M. S. Beer, A. J. Noble, D. N. Middlemiss, L. L. Iversen, and P. Whiting. Molecular cloning of a sertonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype. Proceedings of the National Academy of Sciences USA 89:5517-5521 (1992).

  133. Adham, N., H. T. Kao, L. E. Schecter, J. Bard, M. Olsen, D. Urquhart, M. Durkin, P. R. Hartig, R. L. Weinshank, and T. A. Branchek. Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A 90(2):408-412 (1993).

  134. Gerald, C., N. Adham, H. T. Kao, M. A. Olsen, T. M. Laz, L. E. Schechter, J. A. Bard, P. J. Vaysse, P. R. Hartig, T. A. Branchek, and et al. The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants. Embo J 14(12):2806-2815 (1995).

  135. Hoyer, D., and H. C. Neijt. Identification of serotonin 5-HT3 recognition sites in membranes of N1E- 115 neuroblastoma cells by radioligand binding. Mol Pharmacol 33(3):303-309 (1988).

  136. Amlaiky, N., J. L. Plassat, S. Ramboz, U. Boschert, and R. Hen. The mouse 5-HT5 and 5-HT6 receptors: two new "5-HT1D-like" serotonin receptors:cloning and expression. Society for Neurosciences Abstracts 18:212 (1992).

  137. Hamik, A., D. Oksenberg, C. Fischette, and S. J. Peroutka. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry 28(2):99-109 (1990).

  138. Malmberg, A., G. Nordvall, A. Johansson, N. Mohell, and U. Hacksell. Molecular basis for the binding of 2-aminotetralins to human dopamine D2A and D3 receptors. Molecular Pharmacology 46:299-312 (1994).

  139. Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12.

  140. Laduron PM, Janssen PF, Leysen JE. Spiperone: a ligand of choice for neuroleptic receptors. 3. Subcellular distribution of neuroleptic drugs and their receptors in various rat brain areas. Biochem Pharmacol. 1978 Feb 1;27(3):323-8. No abstract available.

  141. Flores, C. M., M. I. Davila-Garcia, Y. M. Ulrich, and K. J. Kellar. Differential regulation of neuronal nicotinic receptor binding sites following chronic nicotine administration. J Neurochem 69(5):2216-2219 (1997).

  142. Ernsberger, P., L. Iacovitti, and D. J. Reis. Astrocytes cultured from specific brain regions differ in their expression of adrenergic binding sites. Brain Res 517(1-2):202-208 (1990).

  143. London, E. D., and J. T. Coyle. Specific binding of [3H]-kaininc acid to receptor sites in rat brain. Molecular Pharmacology 15:492-505 (1979).

  144. Scheibe, S. D., D. B. Bennett, J. W. Spain, B. L. Roth, and C. J. Coscia. Kinetic evidence for differential agonist and antagonist binding to bovine hippocampal synaptic membrane opioid receptors. J Biol Chem 259(21):13298-303 (1984).

  145. Pryhuber, K. G., B. L. Roth, and C. J. Coscia. Demonstration of a slowly dissociating form of bovine hippocampal synaptic membrane opiate receptors. Eur J Pharmacol 83(1-2):47-53 (1982).

  146. Spain, J. W., D. B. Bennett, B. L. Roth, and C. J. Coscia. Ontogeny of benzomorphan-selective sites: a computerized analysis. Life Sciences 33(Suppl. 1):235-239 (1983).

  147. Roth, B. L., M. B. Laskowski, and C. J. Coscia. Evidence for distinct subcellular sites of opiate receptors. Journal of Biological Chemistry 256:10117-10123 (1981).

  148. Ernsberger, P., and M. A. Haxhiu. The I1-imidazoline-binding site is a functional receptor mediating vasodepression via the ventral medulla. Am J Physiol 273(5):R1572-R1579 (1997).

  149. Ernsberger, P., J. E. Friedman, and R. J. Koletsky. The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. J Hypertens Suppl 15(1):S9-S23 (1997).

  150. Ziegler, D., M. A. Haxhiu, E. C. Kaan, J. G. Papp, and P. Ernsberger. Pharmacology of moxonidine, an I1-imidazoline receptor agonist. J Cardiovasc Pharmacol 27:S26-S37 (1996).

  151. Ernsberger, P., M. E. Graves, L. M. Graff, N. Zakieh, P. Nguyen, L. A. Collins, K. L. Westbrooks, and G. G. Johnson. I1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling. Ann N Y Acad Sci 763:22-42 (1995).

  152. Ernsberger, P., J. E. Piletz, L. M. Graff, and M. E. Graves. Optimization of radioligand binding assays for I1-imidazoline sites. Ann N Y Acad Sci 763:163-168 (1995).